The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. - Wikidata - wikimedia - TriplyDB

The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year.

The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year.

http://www.wikidata.org/entity/Q42955715

about

Making the next steps in psoriatic arthritis management: current status and future directions Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis The use of tumour necrosis factor alpha-blockers in daily routine. An Austrian consensus project.The GOLMePsA study protocol: an investigator-initiated, double-blind, parallel-group, randomised, controlled trial of GOLimumab and methotrexate versus methotrexate in early diagnosed psoriatic arthritis using clinical and whole body MRI outcomes Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT.Infliximab in the treatment of plaque type psoriasis.Infliximab: 12 years of experience Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study.Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes.Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure.Anti-tumor necrosis factor (TNF) drugs for the treatment of psoriatic arthritis: an indirect comparison meta-analysis.TNFalpha blockade in human diseases: an overview of efficacy and safety.The evaluation of psoriasis therapy with biologics leads to a revision of the current view of the pathogenesis of this disorder.The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy.Tumor necrosis factor as a therapeutic target of rheumatologic disease.National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening.Infliximab (Remicade) in the treatment of psoriatic arthritis.TNF-α Promoter Polymorphisms Predict the Response to Etanercept More Powerfully than that to Infliximab/Adalimumab in Spondyloarthritis.Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years.Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol.The efficacy and safety of golimumab in the treatment of arthritis.Emerging drugs for psoriatic arthritis.Combination systemic therapies in psoriatic arthritis.Structural damage in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future.Management of psoriasis and psoriatic arthritis in a combined dermatology and rheumatology clinic.Management of psoriatic arthritis from the view of the dermatologist.Acrodermatitis continua of Hallopeau: evolution of treatment options.Imaging in psoriatic arthritis.Burden of disease: psoriasis and psoriatic arthritis.Diagnosing and treating psoriatic arthritis: an update.Ustekinumab for the treatment of psoriatic arthritis.Ustekinumab : targeting the IL-17 pathway to improve outcomes in psoriatic arthritis.Treatment of psoriatic arthritis with anti-TNF agents: a systematic review and meta-analysis of efficacy, effectiveness and safety.Tumour necrosis factor inhibitors in the treatment of psoriatic arthritis: a view on effectiveness, clinical practice and toxicity.Efficacy and safety of biologics in the treatment of moderate to severe psoriasis: a comprehensive meta-analysis of randomized controlled trials.Certolizumab pegol for the treatment of psoriatic arthritis.Progress in understanding and utilizing TNF-α inhibition for the treatment of psoriatic arthritis.Novel approaches to biological therapy for psoriatic arthritis.Tumor necrosis factor inhibitors in psoriatic arthritis.Disease activity states of the DAPSA, a psoriatic arthritis specific instrument, are valid against functional status and structural progression.

P2860

Q26783506-BBD9CD57-C5E5-472F-9E4E-94779FA87AC1 Q27693878-11139BDD-A111-4A09-A0A4-F73CBE6000CF Q33554356-C4CCB7C0-1686-46B7-875F-500FE0B2B5E7 Q33916770-293FC710-AF4C-47C9-8CC0-08B8CF70881C Q34027596-FF13AE5D-40B2-4B4F-B8C3-78662E41E097 Q34620291-7297202E-771B-44D1-A175-E848341C8750 Q35070446-26614508-088E-4DDC-95C9-BF959B91F6E1 Q35819025-2B594EA1-5FAB-40FE-95F8-13DAAC0C6B79 Q35954535-EDE04221-DE72-4EA4-B426-57FB01052883 Q36182389-A50CFFC9-93E9-425C-99C3-813FE17E01B3 Q36479450-C6587264-58CA-4BD7-90DA-6D9B45B764E7 Q36536861-ED7F795E-1FB9-4998-A042-AE26FBF9EE87 Q36653650-FE0E314A-FA8A-437F-AB1F-EB5423745D9E Q36940942-058A27BD-EBBF-45CF-A945-2B631704A327 Q37008829-5765BBC6-E415-4978-BEB0-D956E4B677DF Q37027264-EACFDDE7-F4E5-4B90-A753-E1B064139F7E Q37116853-AB431938-DE2E-4F1E-A595-63F1EA1B6DC6 Q37220061-BB9CC860-0A97-43A3-9973-58456EA8AA3B Q37350944-D53E74CD-DDE3-43BB-9F8E-E086587C87C5 Q37465379-80A84A20-72C0-4832-8016-1727D9B89114 Q37760938-385D4080-6830-4749-BE65-BE7A4264FC0C Q37763192-B1179EA3-3F4B-448B-97EA-8E548E15DFC4 Q37776265-BD05922B-4C55-46C5-9E80-481555516183 Q37882064-EE25059C-0B09-4F92-8A14-764DCF11FD41 Q37929647-C91747E1-3360-43A9-AB71-D28C4D479732 Q37930978-A4A7EBCB-0D7D-4CD2-9939-68ED0902FFFB Q37939197-BA6E84D2-EAF6-46C0-B073-0A7963366E7E Q37980390-B9F70C67-C6B7-430D-8293-423305366059 Q38114850-B4B1436D-11E5-4BA1-9079-D160F4A469D0 Q38165235-BD0A3392-05E3-46B3-8B0B-B2CA1DD43886 Q38177336-F4F2FBBA-A644-48B5-B647-85A0228265F4 Q38189853-AF124CFE-E647-46F8-94F0-9455395BB13C Q38204241-A7E86294-1B26-4581-B399-1FA1D8A57E0E Q38264660-AB9EF2D7-4A55-4D6D-8161-D0ED9A798268 Q38268725-4F0557BE-ACF1-42D4-B668-5FC290076268 Q38344194-BB708355-05CB-4114-8367-7A59FEFF7EE8 Q38630548-1F42850E-05C1-4EC7-9220-A0DB796005D3 Q38634276-40C80257-33A7-4E60-BFB2-F1DC889D8CE2 Q38685543-94AC0017-77F7-4E44-8B34-F57A01BAE35B Q38837923-B2564670-B05D-46EE-B001-E9C0FA22C516

P2860

The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year.

http://www.wikidata.org/entity/Q42955715

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

The Infliximab Multinational P ...... graphic analyses after 1 year.

@en

The Infliximab Multinational Psoriatic Arthritis Controlled Trial

@nl

type

label

The Infliximab Multinational P ...... graphic analyses after 1 year.

@en

The Infliximab Multinational Psoriatic Arthritis Controlled Trial

@nl

prefLabel

The Infliximab Multinational P ...... graphic analyses after 1 year.

@en

The Infliximab Multinational Psoriatic Arthritis Controlled Trial

@nl

P1433

Q42955715-241F6F6E-4C67-421E-9E2A-ED2C2D6A5B5F

P1476

Q42955715-D22F6DC4-7B23-4640-B4CA-A4E1C40FF6AA

P2093

Q42955715-00DF0AF3-5DD4-4670-8112-17911F7B5447

Q42955715-02869463-0495-49C3-B662-27EC8F52D2DE

Q42955715-4FD40F4C-967E-484E-B011-01B7FC9D7EB6

Q42955715-531C40E9-C584-45E5-9D1D-741B4385B25C

Q42955715-70353C18-6351-49F8-8E42-5CABDBDA6FE4

Q42955715-A7BDB93F-C99C-4444-8657-2E4BAC0A81AC

Q42955715-AC01DAC9-495C-46D2-AFA8-87E9E864EB36

Q42955715-B4908834-632A-447C-B61E-5E74FDF174BF

Q42955715-CC432B63-81C2-4EF0-BD62-0DCFA12AFBBB

Q42955715-DF8E937B-92D7-4A66-AA0B-9F144B6408FA

P2860

Q42955715-0F90BCFE-FE9D-4C1F-8926-6B102DFAF164

Q42955715-2B2DA076-F06B-4C55-9872-45F61102685B

Q42955715-39E2B724-12F1-4BF1-A010-5060C246A4F9

Q42955715-460699E4-DA87-4949-998B-1176BA2277F8

Q42955715-5556B631-7A8C-4433-97E3-2FBE10143110

Q42955715-5CE7DC78-427E-4619-990D-C84C159CA660

Q42955715-6DBC2154-0695-4600-96E8-C8DA2DACE3BA

Q42955715-78E4A094-92D8-46C0-AA48-442FACE04A95

Q42955715-8279BC0F-EB47-4B7D-B90E-AB23248920FA

Q42955715-AF515451-92DD-4334-8328-2BEC4E0B90D8

P304

Q42955715-DAE5CD9E-3067-4DB5-AA6C-48A168E61F38

P31

Q42955715-CE571BB7-065C-4CBF-AAB5-9D3BBA75C1B2

P356

Q42955715-B983AF49-4157-434A-9B78-19AFA99F31CA

P407

Q42955715-10278D48-C430-4E89-AA13-57A4F5DD0D21

P433

Q42955715-5B812A7D-2E0C-43D8-AB6D-E3C320DC0085

P478

Q42955715-E4FF3CA3-873B-42F9-9383-6166209FF6A9

P50

Q42955715-77CBF086-3323-439E-A532-A4607E14E2DD

Q42955715-A40A5FD7-F03A-4A4E-80D3-B52C76266221

P577

Q42955715-E65B83B0-6D0E-4363-A51B-5485433B9CE2

P5875

Q42955715-B5767210-0D1F-4492-963D-18876282FA4E

P698

Q42955715-8B74FF61-0546-44F5-81BD-8341C9A1E20F

P932

Q42955715-86C8541B-88FE-4153-915B-64ECB98B6C2A

P356

ARD.2005.045658

P1433

Annals of the Rheumatic Diseases

P1476

The Infliximab Multinational P ...... graphic analyses after 1 year.

@en

P2093

A Beutler

http://www.w3.org/2001/XMLSchema#string

A Kavanaugh

http://www.w3.org/2001/XMLSchema#string

B Zhou

http://www.w3.org/2001/XMLSchema#string

C E Antoni

http://www.w3.org/2001/XMLSchema#string

D E Furst

http://www.w3.org/2001/XMLSchema#string

D van der Heijde

http://www.w3.org/2001/XMLSchema#string

G Keenan

http://www.w3.org/2001/XMLSchema#string

J R Kalden

http://www.w3.org/2001/XMLSchema#string

J Smolen

http://www.w3.org/2001/XMLSchema#string

M H Weisman

http://www.w3.org/2001/XMLSchema#string

P2860

Methodological issues in radiographic scoring methods in rheumatoid arthritis.

The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiat

T cell derived cytokines in psoriatic arthritis synovial fluids.

Operational definitions and observer reliability of the plain radiographic features of psoriatic arthritis.

Assessment of patients with psoriatic arthritis: a review of currently available measures.

Assessment of radiographs in longitudinal observational studies.

Quantification of radiological damage in inflammatory arthritis: rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.

Immunopathology of psoriasis and psoriatic arthritis

Ethical and practical issues in conducting clinical trials in psoriasis and psoriatic arthritis

Longitudinal study of clinical and radiological progression in psoriatic arthritis.

P304

1038-1043

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/ARD.2005.045658

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

65

http://www.w3.org/2001/XMLSchema#string

P50

Dafna D. Gladman

Gerd-Rüdiger Burmester

P577

2006-01-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7335077

http://www.w3.org/2001/XMLSchema#string

P698

16439444

http://www.w3.org/2001/XMLSchema#string

P932

1798249

http://www.w3.org/2001/XMLSchema#string